Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CLEVELAND, OHIO, March 30, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed...
-
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) --...
-
New York, NY, March 30, 2026 (GLOBE NEWSWIRE) -- Future Money Acquisition Corporation (NASDAQ: FMACU) (the “Company”) today announced the closing of its initial public offering of 11,200,000 units...
-
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- KPET Ultra Paceline Corporation (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of...
-
New York, NY, March 30, 2026 (GLOBE NEWSWIRE) -- QDRO Acquisition Corp. (Nasdaq: QADRU) (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share...
-
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued...
-
GRAND CAYMAN, Cayman Islands, March 30, 2026 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world...
-
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company...
-
Record revenue of $119.9 million, up 21.1% YOY Record 426 boats sold in 2025, up 33% YOYIncreased 2026 revenue guidance to $150–$155 millionSuccessfully completed IPO, strengthening balance sheet and...
-
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement,...